Caffeine-fuelled fix for runaway eye treatment


Cocrystallising sulfacetamide (left) with caffeine (right) makes it less soluble

Eye infection treatments that resist being blinked away could be formulated by cocrystallising an antibiotic with caffeine.

Sulfacetamide (SACT) is often lost on blinking and in tears when applied as a treatment for conjunctivitis and other ocular ailments. This leads to the inconvenience and complications of applying larger and more frequent doses of SACT.

Various schemes have been investigated, including trapping SACT in bioadhesive microspheres, to slow drug release and prevent its washout. But these either limited the drug’s bioavailability or weren’t suitable to market.

To solve the problem, Ashwini Nangia and colleagues at the University of Hyderabad in India, looked to cocrystals. Crystallising an existing drug with another safe substance can change the physicochemical properties of a medicine without having to change the drug molecule itself.

The team reasoned that replacing weaker hydrogen bonds in the crystals with stronger ones could lower the crystal’s solubility and dissolution rate. A selection of molecules were therefore cocrystallised with SACT. Caffeine proved to be one of the most successful, making the drug less soluble and the crystals denser – suggesting the molecules packed tighter together – compared to SACT alone. After studying the hydrogen bonding in SACT and in the cocrystal, stronger N–H---O bonds in the latter (compared to C–H---O) were found to cause the denser crystal packing and lower solubility.

Sulfacetamide and caffeine molecules pack together tighter than sulfacetamide alone

Srinivasulu Aitipamula, a pharmaceutical cocrystal expert at the Institute of Chemical and Engineering Sciences, Singapore, explains that the the identification of intermolecular interactions which can be altered by cocrystal formation is what makes this research stand out. ‘Whereas such design strategies are very well established, the fact that the same strategies have been applied to a less explored area of reducing the solubility/dissolution rate of the drug for improved therapeutic action makes this study noteworthy.’

References

This paper is free to access until 12 May 2014. Download it here:

A Nangia et al, CrystEngComm, 2014, DOI: 10.1039/c4ce00103f


Related Content

Caffeine

2 November 2010 Podcast | Compounds

news image

This week's podcast is about caffeine

Seeding removes barrier to curious cocrystal

20 August 2013 Research

news image

The caffeine•benzoic acid cocrystal that has eluded scientists for 60 years has finally been crystallised

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

First flexible graphene display paves the way for folding electronics

11 September 2014 News and Analysis

news image

Team behind the bendy e-reader display hope to have a full colour graphene-based smartphone style screen within a year

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow